芪参益气滴丸对冠状动脉介入术后炎症因子及心脏不良事件的影响

目的 观察芪参益气滴丸对急性冠脉综合征（ACS）患者经皮冠状动脉介入术（PCI）后炎症因子及主要不良心脏事件（MACE,包括复发心绞痛、急性心肌梗死、严重心律失常、心力衰竭、冠心病死亡）影响.方法纳入60例行PCI的ACS患者,随机分为常规治疗组（n=30）和芪参益气滴丸联合常规治疗组（芪参组,n=30）,采用酶联反应吸附法（ELISA法）比较两组术后24h和术后6个月血清高敏C反应蛋白（hs-CRP）、可溶性CD40配体（sCD40L）及基质金属蛋白酶-9（MMP-9）水平变化,并比较两组6个月MACE事件发生率.结果术后24h两组血清hs-CRP、sCD40L和MMP-9水平均无统计学差异（P＞0.05）;6个月后,两组hs-CRP、sCD40L和MMP-9水平分别是3.18±0.71mg/l、5.86±2.01 ng/dl和240.56±60.6 ng/dl.与对照组相比,芪参组血清hs-CRP、sCD40L及MMP-9均明显降低,差异有统计学意义（P＜0.05）,随访6个月,芪参组MACE发生率较对照组更低（13.33% vs.26.67%,P＜0.05）,且差异有统计学意义.结论 芪参益气滴丸可降低介入术后炎症因子hs-CRP、SCD40L和MMP-9的水平,同时降低MACE近期发生率.

Influences of Qishen Yiqi Gutta Pills on inflammatory factors and major adverse cardiovascular events after percutaneous coronary intervention

Objective To observe the influences of Qishen Yiqi Gutta Pills on inflammatory factors and major adverse cardiovascular events （ MACE ） in the patients with acute coronary syndrome （ ACS ） after percutaneous coronary- intervention （ PCI ） . Methods ACS patients （ rt=60 ） were randomly divided into routine therapy group （ control group ） and Qishen Yiqi Gutta Pills combining routine therapy group （ combining group, each n=30 ） . The changes of high-sensitivity C-reactive protein （ hs-CRP ） , soluble CD40 ligand （ sCD40L ） and matrix metalloproteinase-9 （ MMP-9 ） were cmnpared between two groups by using enzyme-linked immunosorbent assay （ EL1SA ） 24 hours and 6 months after PCI. The incidence rate of MACE （ including severe arrhythmia, relapsing angina pectoris, non-fatal myocardial infarction and target vessel revascularization ） and mortality were compared between two groups after 6 months. Results The levels of hs-CRP, sCD40L and MMP-9 had no statistical difference between two groups （P〉O.05） 24 hours after PCI. After 6 months, the levels of hs-CRP, sCD40L and MMP-9 were, respectively, 3.18± 0.7hng/1, 5.86 ± 2.01 ng/dl and 240.56 ± 60.6 ng/dl. Compared with control group, the levels of hs-CRP, sCD40L and MMP-9 decreased significantly in combining group （ P〈0.05 ） , and the incidence rate of MACE was lower than that in control group （ 13.33% vs. 26.67%, P〈0.05 ） after 6 months. Conclusion Qishen Yiqi Gutta Pills can reduce the levels of hs-CRP, sCD40L and MMP-9 and short-term incidence rate of MACE after PCI.